Navigation Links
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
Date:6/13/2008

o responded could receive consolidation therapy of 400 mg/m2 of Cloretazine(R) (VNP40101M).

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
3. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
6. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
7. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
8. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
9. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
10. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... Healthcare Products®," today announced the closing of Perrigo,s previously ... 6,809,210 ordinary shares at a public offering price of ... option to purchase up to an additional 888,157 ordinary ... Inc., as representatives of the several underwriters. ...
(Date:11/26/2014)... WOODLANDS, Texas , Nov. 26, 2014 /PRNewswire/ ... ) today announced the completion of previously announced ... $280.0 million.  After fees and estimated offering expenses, ... from the transactions.  The transactions consisted of: ... of common stock, pursuant to a registration statement ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... Multi-Center Phase 1 Trial to Commence -, ... Sheets: ARDC), a company focused on the discovery ... viral,diseases, cancer and inflammatory diseases, today announced that ... status to the,Investigational New Drug (IND) application for ...
... Center of the San Francisco Bay research seeks couples ... ... Reproductive Science Center,of the San Francisco Bay Area, in ... evaluate the safety and effectiveness of,ViaCyte, an investigational product intended ...
Cached Medicine Technology:Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 2Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 3Bay Area Women Sought for Egg Freezing Study 2
(Date:11/27/2014)... children to help with chores while they are home from ... boosts self-esteem, and above all, helps parents maintain a somewhat ... how do you encourage your children to want to help? ... Child Development Journal, there is. The study found that adults’ ... to lend a hand. , The study found that ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... India (PRWEB) November 27, 2014 Ethane ... company, has announced online reputation management service. ... a comprehensive study about the world of internet marketing ... and Yahoo. , Ethane Web Technologies does not ... it first analyzes the project to reach a conclusion ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
(Date:11/27/2014)... 26, 2014 Lintelus, Inc., an ... focused on increasing audience engagement at Convergence Summit ... software platform includes a multitude of interactive features ... a collaborative, interactive multi-screen environment. Best of all, ... in real time on their own device. , ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2
... way mothers interact with their babies in the first year ... on. Both a mother,s parenting style and an infant,s temperament ... Lahey and his team from the University of Chicago in ... in Springer,s Journal of Abnormal Child Psychology . , ...
... As part of an initiative to,give back to ... its annual,scientific meetings, the American Society for Therapeutic ... Community - Greater Boston,to raise awareness of cancer ... will join forces with ASTRO by,participating in the ...
... announced today that it has opened a Center for ... Company,s third in the state of,California, one of many ... this location represents the 7th new Center opened in ... According to the National Institute of Health, the ...
... of EP and large untreated patient population to drive ... market, according to Millennium Research Group, ... market will grow significantly over the next five years, ... treatment of cardiac,arrhythmias (a disorder that causes abnormal heart ...
... for Terrorism Preparedness and ... Emergency Response, ... was,selected by the Centers for Disease Control and Prevention (CDC) to ... Emergency Response (COTPER) in Atlanta. This,task order has one base year ...
... N.J., June 23 The American Society of,Transplantation ... the 2008-2009,board of directors. The officers were introduced ... Toronto, Canada, in May., The officers are: ... Medicine; president-elect, Joren C. Madsen, M.D., D.Phil.,Massachusetts General ...
Cached Medicine News:Health News:Mothers' influence is decisive in tots' first year 2Health News:ASTRO, The Wellness Community - Greater Boston Join to Promote Cancer Survivorship 2Health News:CRH Medical Corporation opens Center in San Diego California 2Health News:Chinese Electrophysiology Market to Grow at a CAGR of 20% Over the Next Five Years 2Health News:Lockheed Martin Wins $24 Million IT Contract With CDC 2Health News:The American Society of Transplantation Announces 2008-2009 Board of Directors 2
... PCE PC-Based Exercise ECG Systems offer clinical ... provide advanced database functionality for paperless storage. ... the Welch Allyn PCE Exercise ECG software ... test system. And with its ability to ...
Versatile and Affordable: The Quinton Q-710 ECG system is a versatile and affordable ECG cart that can be configured to meet your specific needs. It can be set on a counter top or mounted on a sturd...
... testing system from Del Mar Reynolds Medical. ... or bicycle ergometer, PC, Cart, isolation transformer ... the same CardioDirect patient interface module that ... ,The system is also available using the ...
... ECT WS 2000 is designed to monitor, store ... provocative tests, (stress-testing). The system can organize the ... provide them for a quick review and printout ... recorded ECG is transmitted via a small portable ...
Medicine Products: